1JK Stock Overview
A commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Apellis Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.57 |
| 52 Week High | US$55.00 |
| 52 Week Low | US$21.57 |
| Beta | 0.92 |
| 1 Month Change | -18.08% |
| 3 Month Change | -30.91% |
| 1 Year Change | -57.72% |
| 3 Year Change | -51.21% |
| 5 Year Change | -8.14% |
| Change since IPO | -1.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1JK | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.6% | 0.4% | -1.3% |
| 1Y | -57.7% | -14.3% | 13.1% |
Return vs Industry: 1JK underperformed the German Biotechs industry which returned -12.7% over the past year.
Return vs Market: 1JK underperformed the German Market which returned 13.3% over the past year.
Price Volatility
| 1JK volatility | |
|---|---|
| 1JK Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.1% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 1JK has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 1JK's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 708 | Cedric Francois | apellis.com |
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA.
Apellis Pharmaceuticals, Inc. Fundamentals Summary
| 1JK fundamental statistics | |
|---|---|
| Market cap | €2.80b |
| Earnings (TTM) | -€182.90m |
| Revenue (TTM) | €722.22m |
3.9x
P/S Ratio-15.3x
P/E RatioIs 1JK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1JK income statement (TTM) | |
|---|---|
| Revenue | US$781.37m |
| Cost of Revenue | US$445.29m |
| Gross Profit | US$336.07m |
| Other Expenses | US$533.95m |
| Earnings | -US$197.88m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.58 |
| Gross Margin | 43.01% |
| Net Profit Margin | -25.32% |
| Debt/Equity Ratio | 198.1% |
How did 1JK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/24 05:38 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Apellis Pharmaceuticals, Inc. is covered by 35 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Michael Ulz | Baird |
| Ishan Majumdar | Baptista Research |